Optimizing Precision Medicine for Patients With Lung and Thyroid Cancer: Guidance for the Multidisciplinary Team
Download these slides from an interdisciplinary workshop series to get up to date on the latest data informing optimal biomarker testing and targeted treatment strategies for lung or thyroid cancers harboring a RET alteration or NTRK fusion.
Chief, Early-Phase Drug Development Sarah Cannon Research Institute Nashville, Tennessee
Vamsidhar Velcheti, MD
Professor of Medicine NYU Grossman School of Medicine Medical Director Thoracic Oncology Program Laura and Isaac Perlmutter Cancer Center An NCI-designated Comprehensive Cancer Center New York, New York
Provided by Clinical Care Options, LLC in Partnership with the American Society for Clinical Pathology
Supported by an educational grant from Lilly.
American Society for Clinical Pathology
Select date of attendance
Welcome to the CCO site
Thank you for your interest in CCO content. As a guest, please complete the following information. This data helps ensure our continued delivery of impactful medical education.
You will be sent to the previous page if you close this window.